Abstract
Subgroup analyses in clinical trials sometimes reveal gender-/sex-dependent differences in cancer outcomes. However, drug approvals are rarely restricted to a specific sex or gender, and recommendations regarding dosage are rarely tailored accordingly. Furthermore, discrepancies exist between the gender-/sex-dependent enrollment rates in clinical trials and real-world incidence or mortality rates. This article highlights gender-/sex differences in clinical trials in uro-oncology.
| Translated title of the contribution | Gender-/Sex-Specific Differences in Clinical Trials in Uro-Oncology |
|---|---|
| Original language | German |
| Journal | Aktuelle Urologie |
| Volume | 56 |
| Issue number | 2 |
| Pages (from-to) | 131-134 |
| Number of pages | 4 |
| ISSN | 0001-7868 |
| DOIs | |
| Publication status | Published - 28.01.2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being -
SDG 5 Gender Equality
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
DFG Research Classification Scheme
- 2.22-23 Reproductive Medicine, Urology
- 2.22-14 Hematology, Oncology
Fingerprint
Dive into the research topics of 'Gender-/Sex-Specific Differences in Clinical Trials in Uro-Oncology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver